Impavido miltefosine: Phase III; marketed in India to treat visceral Leishmaniasis

In a double-blind Phase III trial in 133 patients in Columbia and Guatemala, Impavido had a 220% better cure than placebo (p<0.001). After 6 months, the average cure rate for Impavido patients was 70%...